Amarin Corp Plcuk (AMRN) Preferred Shares (2015 - 2020)
Amarin Corp Plcuk (AMRN) reported Preferred Shares of $5.4 million for Q3 2020, down 75.13% year-over-year from $21.8 million in Q4 2019, and down 24.17% quarter-over-quarter from $7.2 million in Q2 2020.
Amarin Corp Plcuk (AMRN) Preferred Shares (2015 - 2020) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 6 years of Preferred Shares data on file, last reported at $5.4 million in Q3 2020.
- Preferred Shares for Q3 2020 came in at $5.4 million, down 75.13% year-over-year; the trailing twelve-month figure through Sep 2020 was $5.4 million (down 75.13% YoY), and the FY2019 annual result was $21.8 million, changed 0.0% from the prior year.
- Preferred Shares fell to $5.4 million in Q3 2020 per AMRN's latest filing, from $7.2 million in the prior quarter.
- Over five years, Preferred Shares peaked at $24.4 million in Q1 2016 and troughed at $5.4 million in Q3 2020.
- A 5-year average of $21.5 million and a median of $24.4 million in 2016 frame the typical range for Preferred Shares.
- The sharpest annual moves came in 2016 and 2020: Preferred Shares increased 13.98% in 2016, then plunged 75.13% in 2020.
- A 5-year view of Preferred Shares shows it stood at $24.4 million in 2016, then changed by 0.0% to $24.4 million in 2017, then fell by 10.32% to $21.8 million in 2018, then changed by 0.0% to $21.8 million in 2019, then tumbled by 75.13% to $5.4 million in 2020.
- Business Quant data shows AMRN's Preferred Shares at $5.4 million in Q3 2020, $7.2 million in Q2 2020, and $21.8 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 5.43 Mn |
| Jun 30, 2020 | 7.17 Mn |
| Mar 31, 2020 | 21.85 Mn |
| Dec 31, 2019 | 21.85 Mn |
| Sep 30, 2019 | 21.85 Mn |
| Jun 30, 2019 | 21.85 Mn |
| Mar 31, 2019 | 21.85 Mn |
| Dec 31, 2018 | 21.85 Mn |
| Sep 30, 2018 | 21.85 Mn |
| Jun 30, 2018 | 24.36 Mn |
| Mar 31, 2018 | 24.36 Mn |
| Dec 31, 2017 | 24.36 Mn |
| Sep 30, 2017 | 24.36 Mn |
| Jun 30, 2017 | 24.36 Mn |
| Mar 31, 2017 | 24.36 Mn |
| Dec 31, 2016 | 24.36 Mn |
| Sep 30, 2016 | 24.36 Mn |
| Jun 30, 2016 | 24.36 Mn |
| Mar 31, 2016 | 24.36 Mn |
| Dec 31, 2015 | 24.36 Mn |